These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38023561)

  • 21. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.
    Günthard HF; Aberg JA; Eron JJ; Hoy JF; Telenti A; Benson CA; Burger DM; Cahn P; Gallant JE; Glesby MJ; Reiss P; Saag MS; Thomas DL; Jacobsen DM; Volberding PA;
    JAMA; 2014 Jul 23-30; 312(4):410-25. PubMed ID: 25038359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey.
    Moyo S; Hunt G; Zuma K; Zungu M; Marinda E; Mabaso M; Kana V; Kalimashe M; Ledwaba J; Naidoo I; Takatshana S; Matjokotja T; Dietrich C; Raizes E; Diallo K; Kindra G; Mugore L; Rehle T
    PLoS One; 2020; 15(11):e0241071. PubMed ID: 33147285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
    de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
    Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
    Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
    HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
    Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
    Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
    J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.
    Gil H; Delgado E; Benito S; Moreno-Lorenzo M; Thomson MM;
    Front Microbiol; 2022; 13():1051096. PubMed ID: 36578581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens.
    Rhee SY; Clutter D; Hare CB; Tchakoute CT; Sainani K; Fessel WJ; Hurley L; Slome S; Pinsky BA; Silverberg MJ; Shafer RW
    Open Forum Infect Dis; 2020 Sep; 7(9):ofaa316. PubMed ID: 32904894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.
    De La Mata NL; Cooper DA; Russell D; Smith D; Woolley I; Sullivan MO; Wright S; Law M
    Sex Health; 2016 Apr; ():. PubMed ID: 27097796
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay-Results of a Nationally Representative Survey, 2018-2019.
    Flieller R; Cabrera S; Ruchansky D; Girón-Callejas A; Brasesco M; Pérez D; Chiparelli H; García-Morales C; Tapia-Trejo D; Monreal-Flores J; Ravasi G; Jordan MR; Ávila-Ríos S
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
    Mendoza Y; Castillo Mewa J; Martínez AA; Zaldívar Y; Sosa N; Arteaga G; Armién B; Bautista CT; García-Morales C; Tapia-Trejo D; Ávila-Ríos S; Reyes-Terán G; Bello G; Pascale JM
    PLoS One; 2016; 11(4):e0154317. PubMed ID: 27119150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
    Obasa AE; Mikasi SG; Brado D; Cloete R; Singh K; Neogi U; Jacobs GB
    Front Microbiol; 2020; 11():438. PubMed ID: 32265875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and durability of nevirapine in antiretroviral drug näive patients.
    Lange JM
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S40-52. PubMed ID: 14562857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018.
    McClung RP; Oster AM; Ocfemia MCB; Saduvala N; Heneine W; Johnson JA; Hernandez AL
    Clin Infect Dis; 2022 Mar; 74(6):1055-1062. PubMed ID: 34175948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool.
    Ramirez JA; Maddali MV; Budak JZ; Li JZ; Lampiris H; Shah M
    J Gen Intern Med; 2020 May; 35(5):1498-1503. PubMed ID: 31792870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.